BIG
BCRX icon

Brooklyn Investment Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Brooklyn Investment Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,708
Closed -$144K – 1856
2025
Q4 		$144K Buy
+18,708
New +$135K 0.01% 1429
2025
Q1 		– Sell
-1,080
Closed -$8.12K – 2779
2024
Q4 		$8.12K Buy
+1,080
New +$8.2K ﹤0.01% 1066

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Brooklyn Investment Group's BCRX Position: Q1 2026 in Review

Brooklyn Investment Group sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2026, closing a stake of 18,708 shares — an estimated $144K sold.

Brooklyn Investment Group first reported a position in BCRX in Q4 2024 and held it in 2 quarters. The position peaked at $144K in Q4 2025. 302 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Brooklyn Investment Group reported no remaining BioCryst Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Brooklyn Investment Group sold 18,708 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $144K.
  • Brooklyn Investment Group first reported a position in BioCryst Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Brooklyn Investment Group's BioCryst Pharmaceuticals position peaked at $144K in Q4 2025.
  • 302 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Brooklyn Investment Group's 13F filing for Q1 2026, filed 29 Apr 2026.